{"transactions":[{"id":709095,"issuer":{"id":29892,"kind":"organization","name":"Nuvalent, Inc.","symbol":"NUVL"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-15T23:11:31.000Z","date":"2026-07-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4147,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a \"Company Stock Option\") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a \"Company Stock Option\") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":75.53,"expiration_date":"2035-06-18","underlying":"Class A Common Stock","underlying_shares":4147},"source":{"system":"sec-edgar","filing":"0001193125-26-305095","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1861560/000119312526305095/ownership.xml","form_type":"4"}},{"id":709094,"issuer":{"id":29892,"kind":"organization","name":"Nuvalent, Inc.","symbol":"NUVL"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-15T23:11:31.000Z","date":"2026-07-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3789,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a \"Company Stock Option\") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a \"Company Stock Option\") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":80.03,"expiration_date":"2034-06-12","underlying":"Class A Common Stock","underlying_shares":3789},"source":{"system":"sec-edgar","filing":"0001193125-26-305095","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1861560/000119312526305095/ownership.xml","form_type":"4"}},{"id":709093,"issuer":{"id":29892,"kind":"organization","name":"Nuvalent, Inc.","symbol":"NUVL"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-15T23:11:31.000Z","date":"2026-07-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a \"Company Stock Option\") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a \"Company Stock Option\") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":44.68,"expiration_date":"2033-06-15","underlying":"Class A Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193125-26-305095","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1861560/000119312526305095/ownership.xml","form_type":"4"}},{"id":709092,"issuer":{"id":29892,"kind":"organization","name":"Nuvalent, Inc.","symbol":"NUVL"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-15T23:11:31.000Z","date":"2026-07-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a \"Company Stock Option\") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a \"Company Stock Option\") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":19.48,"expiration_date":"2032-10-04","underlying":"Class A Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001193125-26-305095","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1861560/000119312526305095/ownership.xml","form_type":"4"}},{"id":709091,"issuer":{"id":29892,"kind":"organization","name":"Nuvalent, Inc.","symbol":"NUVL"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-15T23:11:31.000Z","date":"2026-07-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8361,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a \"Company Stock Option\") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Common Stock (a \"Company Stock Option\") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the effective time of the Merger and (y) the excess, if any, of the Offer Price over the applicable exercise price per share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":6.89,"expiration_date":"2031-04-29","underlying":"Class A Common Stock","underlying_shares":8361},"source":{"system":"sec-edgar","filing":"0001193125-26-305095","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1861560/000119312526305095/ownership.xml","form_type":"4"}},{"id":709090,"issuer":{"id":29892,"kind":"organization","name":"Nuvalent, Inc.","symbol":"NUVL"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock - Restricted Stock Units","published_at":"2026-07-15T23:11:31.000Z","date":"2026-07-15","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3444,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of Class A Common Stock of the Company."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Pursuant to the Merger Agreement, each restricted stock unit that was subject solely to time-based vesting (a \"Company RSU\") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such Company RSU immediately prior to the effective time of the Merger and (y) the Offer Price."},{"field":"shares","element":"transactionShares","label":"F4","text":"Pursuant to the Merger Agreement, each restricted stock unit that was subject solely to time-based vesting (a \"Company RSU\") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such Company RSU immediately prior to the effective time of the Merger and (y) the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each restricted stock unit that was subject solely to time-based vesting (a \"Company RSU\") that was outstanding immediately prior to the effective time of the Merger, whether or not vested, was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such Company RSU immediately prior to the effective time of the Merger and (y) the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-305095","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861560/000119312526305095/ownership.xml","form_type":"4"}},{"id":709089,"issuer":{"id":29892,"kind":"organization","name":"Nuvalent, Inc.","symbol":"NUVL"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-07-15T23:11:31.000Z","date":"2026-07-15","kind":"other","planned":false,"acquired":false,"shares":5146,"price":124,"value":638104.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated June 9, 2026 (the \"Merger Agreement\"), by and among (i) Nuvalent, Inc., a Delaware corporation (the \"Company\"), (ii) GlaxoSmithKline LLC, a Delaware limited liability company (\"Parent\"), (iii) Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent (\"Purchaser\"), and (iv) solely for purposes of Section 9.14 therein, GSK plc, a public limited company organized under the laws of England and Wales (\"Ultimate Parent\"), Purchaser completed a tender offer (the \"Offer\") to purchase all outstanding shares of Class A Common Stock of the Company and Class B Common Stock of the Company. The shares of Class A Common Stock of the Company and Class B Common Stock of the Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $124.00 per share, net to the seller in cash, without interest (the \"Offer Price\"), subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) After completion of the Offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Company (the \"Merger\"), with the Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated June 9, 2026 (the \"Merger Agreement\"), by and among (i) Nuvalent, Inc., a Delaware corporation (the \"Company\"), (ii) GlaxoSmithKline LLC, a Delaware limited liability company (\"Parent\"), (iii) Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent (\"Purchaser\"), and (iv) solely for purposes of Section 9.14 therein, GSK plc, a public limited company organized under the laws of England and Wales (\"Ultimate Parent\"), Purchaser completed a tender offer (the \"Offer\") to purchase all outstanding shares of Class A Common Stock of the Company and Class B Common Stock of the Company. The shares of Class A Common Stock of the Company and Class B Common Stock of the Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $124.00 per share, net to the seller in cash, without interest (the \"Offer Price\"), subject to applicable withholding tax."},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from footnote 1) After completion of the Offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Company (the \"Merger\"), with the Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated June 9, 2026 (the \"Merger Agreement\"), by and among (i) Nuvalent, Inc., a Delaware corporation (the \"Company\"), (ii) GlaxoSmithKline LLC, a Delaware limited liability company (\"Parent\"), (iii) Harmony Row Acquisition Co., a Delaware corporation and wholly owned subsidiary of Parent (\"Purchaser\"), and (iv) solely for purposes of Section 9.14 therein, GSK plc, a public limited company organized under the laws of England and Wales (\"Ultimate Parent\"), Purchaser completed a tender offer (the \"Offer\") to purchase all outstanding shares of Class A Common Stock of the Company and Class B Common Stock of the Company. The shares of Class A Common Stock of the Company and Class B Common Stock of the Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for $124.00 per share, net to the seller in cash, without interest (the \"Offer Price\"), subject to applicable withholding tax."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) After completion of the Offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Company (the \"Merger\"), with the Company surviving the Merger as a wholly owned subsidiary of Parent."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-305095","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861560/000119312526305095/ownership.xml","form_type":"4"}},{"id":732248,"issuer":{"id":29892,"kind":"organization","name":"Nuvalent, Inc.","symbol":"NUVL"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-06-18T20:32:46.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":3444,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Nuvalent, Inc. Class A Common Stock issuable under restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Nuvalent, Inc. Class A Common Stock. The RSUs vest in full on the earlier of June 16, 2027 or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service to Nuvalent, Inc. through the applicable vesting date."}],"balance_after":8590,"source":{"system":"sec-edgar","filing":"0001664204-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861560/000166420426000002/ownership.xml","form_type":"4"}},{"id":1105132,"issuer":{"id":29892,"kind":"organization","name":"Nuvalent, Inc.","symbol":"NUVL"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:34:48.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":4147,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option vest in full on the earlier of June 18, 2026 or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service to Nuvalent, Inc. through the applicable vesting date."}],"balance_after":4147,"derivative":{"exercise_price":75.53,"expiration_date":"2035-06-18","underlying":"Class A Common Stock","underlying_shares":4147},"source":{"system":"sec-edgar","filing":"0000950170-25-088546","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861560/000095017025088546/ownership.xml","form_type":"4"}},{"id":1105131,"issuer":{"id":29892,"kind":"organization","name":"Nuvalent, Inc.","symbol":"NUVL"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-06-20T20:34:48.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":2647,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Nuvalent, Inc. Class A Common Stock issuable under restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Nuvalent, Inc. Class A Common Stock. The RSUs vest in full on the earlier of June 18, 2026 or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service to Nuvalent, Inc. through the applicable vesting date."}],"balance_after":5146,"source":{"system":"sec-edgar","filing":"0000950170-25-088546","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861560/000095017025088546/ownership.xml","form_type":"4"}},{"id":1479296,"issuer":{"id":29892,"kind":"organization","name":"Nuvalent, Inc.","symbol":"NUVL"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T20:10:57.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":3789,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option vest in full on the earlier of June 12, 2025 or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service to Nuvalent, Inc. through the applicable vesting date."}],"balance_after":3789,"derivative":{"exercise_price":80.03,"expiration_date":"2034-06-12","underlying":"Class A Common Stock","underlying_shares":3789},"source":{"system":"sec-edgar","filing":"0000950170-24-073653","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1861560/000095017024073653/ownership.xml","form_type":"4"}},{"id":1479295,"issuer":{"id":29892,"kind":"organization","name":"Nuvalent, Inc.","symbol":"NUVL"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-06-14T20:10:57.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":2499,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Nuvalent, Inc. Class A Common Stock issuable under restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Nuvalent, Inc. Class A Common Stock. The RSUs vest in full on the earlier of June 12, 2025 or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service to Nuvalent, Inc. through the applicable vesting date."}],"balance_after":2499,"source":{"system":"sec-edgar","filing":"0000950170-24-073653","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861560/000095017024073653/ownership.xml","form_type":"4"}},{"id":1852597,"issuer":{"id":29892,"kind":"organization","name":"Nuvalent, Inc.","symbol":"NUVL"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T20:17:53.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of June 15, 2024 or the date of Nuvalent, Inc.'s next annual meeting of stockholders, subject to continued service to Nuvalent, Inc. through the applicable vesting date."}],"balance_after":15000,"derivative":{"exercise_price":44.68,"expiration_date":"2033-06-15","underlying":"Class A Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-23-037832","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861560/000120919123037832/doc4.xml","form_type":"4"}},{"id":2141411,"issuer":{"id":29892,"kind":"organization","name":"Nuvalent, Inc.","symbol":"NUVL"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T20:30:06.000Z","date":"2022-10-04","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest over the next three years in equal monthly installments following October 4, 2022, subject to continued service to Nuvalent, Inc. through the applicable vesting date."}],"balance_after":40000,"derivative":{"exercise_price":19.48,"expiration_date":"2032-10-04","underlying":"Class A Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-22-052987","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1861560/000120919122052987/doc4.xml","form_type":"4"}},{"id":2413095,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2022-02-03T22:31:53.000Z","date":"2022-02-02","kind":"grant","acquired":true,"shares":17350,"price":15.79,"value":273956.5,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/23rd of the shares subject to the option shall vest monthly over a two-year period."}],"balance_after":17350,"derivative":{"exercise_price":15.79,"expiration_date":"2032-02-02","underlying":"Common Stock","underlying_shares":17350},"source":{"system":"sec-edgar","filing":"0001562180-22-001078","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022001078/primarydocument.xml","form_type":"4"}},{"id":2413094,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-02-03T22:31:53.000Z","date":"2022-01-31","kind":"other","acquired":true,"shares":1714,"price":12.39,"value":21236.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,715 shares by the Reporting Person on 1/31/22 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":23280,"source":{"system":"sec-edgar","filing":"0001562180-22-001078","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022001078/primarydocument.xml","form_type":"4"}},{"id":2453779,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2022-01-03T21:03:08.000Z","date":"2021-12-30","kind":"exercise","acquired":false,"shares":5900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":8.77,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":5900},"source":{"system":"sec-edgar","filing":"0001562180-22-000035","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022000035/primarydocument.xml","form_type":"4"}},{"id":2453778,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-01-03T21:03:08.000Z","date":"2021-12-30","kind":"exercise","acquired":true,"shares":5900,"price":8.77,"value":51743.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person is filing this Form 4 to report the acquisition of shares by the Reporting Person pursuant to the exercise of a stock option grant.  There are no sales to report in this filing."}],"balance_after":21566,"source":{"system":"sec-edgar","filing":"0001562180-22-000035","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218022000035/primarydocument.xml","form_type":"4"}},{"id":2737011,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-28T20:15:00.000Z","date":"2021-04-26","kind":"purchase","acquired":true,"shares":500,"price":15.46,"value":7730.0,"ownership":{"direct":true},"balance_after":15666,"source":{"system":"sec-edgar","filing":"0001562180-21-002976","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021002976/primarydocument.xml","form_type":"4"}},{"id":2876351,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-05T21:21:27.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option shall vest monthly over a four-year period."}],"balance_after":80000,"derivative":{"exercise_price":21.36,"expiration_date":"2031-02-03","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001562180-21-000931","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021000931/primarydocument.xml","form_type":"4"}},{"id":2876350,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-05T21:21:27.000Z","date":"2021-01-31","kind":"other","acquired":true,"shares":1771,"price":12,"value":21252.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,771 shares by the Reporting Person on 01/31/2021 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":15166,"source":{"system":"sec-edgar","filing":"0001562180-21-000931","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021000931/primarydocument.xml","form_type":"4"}},{"id":2876349,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-05T21:21:27.000Z","date":"2020-07-31","kind":"other","acquired":true,"shares":2665,"price":7.97,"value":21240.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 2,665 shares by the Reporting Person on 07/31/2020 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":13395,"source":{"system":"sec-edgar","filing":"0001562180-21-000931","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218021000931/primarydocument.xml","form_type":"4"}},{"id":3086216,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-07-08T20:11:47.000Z","date":"2020-07-06","kind":"grant","acquired":true,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"50% of the shares will vest on July 6, 2021 and the remaining 50% of the shares will vest on July 6, 2022."}],"balance_after":10730,"source":{"system":"sec-edgar","filing":"0001562180-20-005074","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218020005074/primarydocument.xml","form_type":"4"}},{"id":3270005,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-14T21:36:46.000Z","date":"2020-02-12","kind":"grant","acquired":true,"shares":50825,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest monthly over a four-year period."}],"balance_after":50825,"derivative":{"exercise_price":9.47,"expiration_date":"2030-02-12","underlying":"Common Stock","underlying_shares":50825},"source":{"system":"sec-edgar","filing":"0001562180-20-001236","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218020001236/primarydocument.xml","form_type":"4"}},{"id":3579463,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-03-25T20:03:30.000Z","date":"2019-03-21","kind":"purchase","acquired":true,"shares":8,"price":4.87,"value":38.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Amendment filed to correct previously filed Form, which did not include 8 shares purchased in an additional transaction."}],"balance_after":7230,"source":{"system":"sec-edgar","filing":"0001562180-19-002023","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218019002023/primarydocument.xml","form_type":"4/A","original_submission_date":"2019-03-22"}},{"id":3580741,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-03-22T20:05:42.000Z","date":"2019-03-21","kind":"purchase","acquired":true,"shares":104,"price":4.87,"value":506.48,"ownership":{"direct":true},"balance_after":7222,"source":{"system":"sec-edgar","filing":"0001562180-19-002012","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218019002012/primarydocument.xml","form_type":"4"}},{"id":3580740,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-03-22T20:05:42.000Z","date":"2019-03-21","kind":"purchase","acquired":true,"shares":1000,"price":4.93,"value":4930.0,"ownership":{"direct":true},"balance_after":7118,"source":{"system":"sec-edgar","filing":"0001562180-19-002012","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218019002012/primarydocument.xml","form_type":"4"}},{"id":3667686,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-08T21:27:47.000Z","date":"2019-02-06","kind":"grant","acquired":true,"shares":104325,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The securities awarded on 02/06/2019 were in the form of stock options issued pursuant to the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan. Options to purchase 50,825 shares of common stock shall vest in 48 successive equal monthly installments measured from 02/06/2019. Options to purchase 53,500 shares of common stock shall vest periodically upon the Issuer achieving certain milestones."}],"balance_after":104325,"derivative":{"exercise_price":6.38,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":104325},"source":{"system":"sec-edgar","filing":"0001562180-19-000853","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218019000853/primarydocument.xml","form_type":"4"}},{"id":3667685,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-02-08T21:27:47.000Z","date":"2019-01-31","kind":"other","acquired":true,"shares":3720,"price":4.76,"value":17707.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 3,720 shares by the Reporting Person on 01/31/2019 pursuant to the Issuer's Employee Stock Purchase Plan."}],"balance_after":6118,"source":{"system":"sec-edgar","filing":"0001562180-19-000853","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218019000853/primarydocument.xml","form_type":"4"}},{"id":3771368,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-11-07T21:02:10.000Z","date":"2018-10-30","kind":"purchase","acquired":true,"shares":200,"price":4.79,"value":958.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 2,198 shares acquired under the Syndax Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan on 7/31/2018."}],"balance_after":2398,"source":{"system":"sec-edgar","filing":"0001562180-18-004443","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218018004443/primarydocument.xml","form_type":"4"}},{"id":4013984,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-05T21:04:18.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in 48 successive equal monthly installments measured from February 8, 2018."}],"balance_after":75000,"derivative":{"exercise_price":9.4,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001562180-18-001426","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218018001426/primarydocument.xml","form_type":"4"}},{"id":4461197,"issuer":{"id":4578,"kind":"organization","name":"Syndax Pharmaceuticals Inc"},"owners":[{"id":30348,"kind":"person","name":"Meyers Michael L.","position":1,"cik":"0001664204","reported_name":"Meyers Michael L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-08T19:13:05.000Z","date":"2017-02-06","kind":"grant","acquired":true,"shares":66100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest in 48 successive equal monthly installments measured from February 6, 2017."}],"balance_after":66100,"derivative":{"exercise_price":8.77,"expiration_date":"2027-02-06","underlying":"Common Stock","underlying_shares":66100},"source":{"system":"sec-edgar","filing":"0001562180-17-000568","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1395937/000156218017000568/primarydocument.xml","form_type":"4"}}]}